Half standard deviation estimate of the minimally important difference in HRQOL scores?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 5, 2004, Pages 515-523

  Farivar, Sépideh S ^a   Liu, Honghu ^b   Hays, Ron D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinically important differences; Effect size; Health related quality of life; Minimally detectable differences; Minimally important differences; Patient reported outcomes; Self reported health

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; SALMETEROL XINAFOATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYSIS OF VARIANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMOTIONALITY; ENERGY; FATIGUE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; PATIENT ATTITUDE; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SCORING SYSTEM; SOCIAL INTERACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WELLBEING;

EID: 5444246327     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.5.515     Document Type: Review

References (48)

1. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J. Clin. Epi. 56, 395-407 (2003).
2. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin. Proc. 77, 371-383 (2002).
3. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care 41, 582-592 (2003).
4. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual. Life Res. 1, 73-75 (1992).
5. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining the minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 43, 1478-1487 (2000).
6. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well being in chronic dialysis patients. J. Am. Soc. Neph. 7, 763-773 (1996).
7. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research: how meaningful is it? PharmacoEconomics 18, 419-423 (2000).
8. Cohen J. A power primer. Psychol. Bull. 112, 155-159 (1992).
9. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Resp. Crit. Care Med. 155, 1283-1289 (1997).
10. Bagenstose SE, Bernstein JA. Treatment of chronic rhinitis by an allergy specialist improves quality of life outcomes. Ann. Allergy Asthma Immunol. 83, 524-528 (1999).
11. Bestall JC, Paul EA, Garrod R, Gamham R, Joes PW, Wedzicha JA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54, 581-586 (1999).
12. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch. Neurol. 57, 1319-1324 (2000).
13. Singh SJ, Sodergren SC, Hyland ME, Williams J, Morgan MDL. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Resp. Med. 95, 71-77 (2001).
14. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am. J. Gastroenterol. 96, 1998-2004 (2001).
15. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12, 199-220 (1995).
16. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual. Life Res. 11, 207-221 (2002).
17. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intraindividual changes in health-related quality of life. J. Clin. Epi. 52, 861-873 (1999).
18. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med. Care 37, 469-478 (1999).
19. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the 6-minute walk test in chronic lung disease patients. Am. J. Resp. Crit. Care Med. 155, 1278-1282 (1997).
20. Badia Y, Podzamczer D, Casado A. López-Lavid C, Garcia M, Spanish MOS-HIV and MQOL-HIV Validation Group. Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. AIDS 14, 1439-1447 (2000).
21. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 344, 1394-1397 (1994).
22. Jowett SL, Seal CJ, Barton R, Welfare MR. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am. J. Gastroenterol. 96, 2921-2928 (2001).
23. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease. Thorax 52, 67-71 (1997).
24. Bessette L, Sangha O, Kuntz K et al. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. Med. Care. 36, 491-502 (1998).
25. van Doorslaer E, Jones AM. Inequalities in self-reported health: validation of a new approach to measurement. J. Health Econ. 22, 61-87 (2003).
26. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann. Med. 33(5), 344-349 (2001).
27. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BEK. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med. Dec. Making 17 (1), 1-9 (1997).
28. Kaplan RM. The minimally clinically important difference in generic utility-based measures. Prepared for the workshop on minimally clinically important differences in COPD. Bel Harbor, FL, USA. January 11-13 (2004).
29. Pyne JM, Sullivan G, Kaplan R, Williams DK. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med. Care 41 (2), 208-217 (2003).
30. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual. Life Outcomes 1(1), 4 (2003).
31. King M, Dobson A. Estimating the responsiveness of an instrument using more than two repeated measures. Biometrics 56, 1197-1203 (2000).
32. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 7, 1-26 (1979).
33. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for changes in health status. Med. Care 27, S178-S189 (1989).
34. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A, Mowat A. Importance of sensitivity to change as a criterion for selecting health status measures. Qual. Health Care 1, 89-93 (1992).
35. Wells GA, Tugwell P Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J. Rheumatol. 20, 557-566 (1997).
36. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual. Life Res. 5, 35-46 (1996).
37. Wijkstra PJ, Ten Vergert EM, van Altena R et al. Long-term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax 50, 824-828 (1995).
38. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 47, 81-87 (1994).
39. Guell R, Casan P, Sangenis M, Morante F, Belda J, Guyatt GH. Quality of life in patients with chronic respiratory disease: the Spanish version of the chronic respiratory questionnaire. Eur. Respir. J. 11, 55-60 (1998).
40. Patrick DL, Martin ML, Bushnell DM, Yalcin L, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 53, 71-76 (1999).
41. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the health utilities index mark II. PharmacoEconomics 15, 141-155 (1999).
42. Santanello NC, Zhang J, Seidenber B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur. Resp. J. 14, 23-27 (1999).
43. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am. J. Med. 109, 207-212 (2000).
44. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimally clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Care Res. 45, 384-391 (2001).
45. Segal R, Evans W, Johnson D et al. Structured exercise improves physical functioning in women with states I and II breast cancer: results of a randomized controlled trial. J. Clin. Oncol. 19, 657-665 (2001).
46. Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the functional assessment of cancer therapy-lung (FACT-L) questionnaire? results from eastern co-operative oncology group (ECOG) study 5592. J. Clin. Epidemiol. 37, 469-478 (2002).
47. Angst F, Aesclimann A, Michel BA et al. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J. Rheumatol. 29, 131-138 (2002).
48. Wise EA. Methods for analyzing psychotherapy outcomes: a review of clinical significance, reliable change, and recommendations for future directions. J. Pers. Assess. 82, 50-59 (2004).